{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:17:24Z","timestamp":1754108244499},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,12]]},"DOI":"10.7759\/cureus.33685","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T11:27:25Z","timestamp":1673522845000},"source":"Crossref","is-referenced-by-count":2,"title":["The Efficiency and Safety of Mirabegron Monotherapy for the Treatment of Urge Incontinence in Women Aged >80 Years"],"prefix":"10.7759","author":[{"given":"Cihat","family":"\u00d6zcan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adem","family":"Sanc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Beyatl\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selahattin","family":"Bedir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya\u015far","family":"\u00d6zg\u00f6k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.125704","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"187","author":"Abrams P","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, et al.. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002, 187:116-26. 10.1067\/mob.2002.125704","journal-title":"Am J Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.8.986","article-title":"Management of urinary incontinence in women: scientific review","volume":"291","author":"Holroyd-Leduc JM","year":"2004","unstructured":"Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: scientific review. JAMA. 2004, 291:986-95. 10.1001\/jama.291.8.986","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.01.023","article-title":"Urinary incontinence and age at the first and last delivery: the Norwegian HUNT\/EPINCONT study","volume":"195","author":"Rortveit G","year":"2006","unstructured":"Rortveit G, Hunskaar S. Urinary incontinence and age at the first and last delivery: the Norwegian HUNT\/EPINCONT study. Am J Obstet Gynecol. 2006, 195:433-8. 10.1016\/j.ajog.2006.01.023","journal-title":"Am J Obstet Gynecol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley EA","year":"2015","unstructured":"Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment. J Urol. 2015, 193:1572-80. 10.1016\/j.juro.2015.01.087","journal-title":"J Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-013-0509-9","article-title":"The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials","volume":"46","author":"Cui Y","year":"2014","unstructured":"Cui Y, Zong H, Yang C, Yan H, Zhang Y. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014, 46:275-84. 10.1007\/s11255-013-0509-9","journal-title":"Int Urol Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000361079","article-title":"The role of mirabegron in overactive bladder: a systematic review and meta-analysis","volume":"93","author":"Wu T","year":"2014","unstructured":"Wu T, Duan X, Cao CX, Peng CD, Bu SY, Wang KJ. The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Urol Int. 2014, 93:326-37. 10.1159\/000361079","journal-title":"Urol Int"},{"key":"ref7","unstructured":"European Association of Urology. Non-neurogenic female LUTS. (2022). https:\/\/uroweb.org\/guidelines\/non-neurogenic-female-luts."},{"key":"ref8","article-title":"Urinary incontinence medical treatment (Article inTurkish)","volume":"1","author":"Bostanci MS","year":"2015","unstructured":"Bostanci MS, \u00d6zden S, \u00dcnal O, Cevri\u0307o\u011flu AS, Akdemi\u0307r N. Urinary incontinence medical treatment (Article inTurkish). J Hum Rhythm. 2015, 1:83-9.","journal-title":"J Hum Rhythm"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-014-0237-6","article-title":"Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients","volume":"32","author":"Wagg A","year":"2015","unstructured":"Wagg A, Oelke M, Angulo JC, Scholfield D, Arumi D. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients. Drugs Aging. 2015, 32:103-25. 10.1007\/s40266-014-0237-6","journal-title":"Drugs Aging"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-00989-7","article-title":"Mirabegron for overactive bladder in frail patients 80\u00a0years or over (HOKUTO study)","volume":"22","author":"Nakagomi H","year":"2022","unstructured":"Nakagomi H, Mitsui T, Shimura H, Ihara T, Kira S, Sawada N, Takeda M. Mirabegron for overactive bladder in frail patients 80\u00a0years or over (HOKUTO study). BMC Urol. 2022, 22:40. 10.1186\/s12894-022-00989-7","journal-title":"BMC Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.13465","article-title":"Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities","volume":"18","author":"Lee YK","year":"2018","unstructured":"Lee YK, Kuo HC. Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Geriatr Gerontol Int. 2018, 18:1330-3. 10.1111\/ggi.13465","journal-title":"Geriatr Gerontol Int"},{"key":"ref12","article-title":"OAB-V8 overactive bladder inquiry form validation study (Article in Turkish)","volume":"21","author":"Tarcan T","year":"2012","unstructured":"Tarcan T, Mang\u0131r N, \u00d6zg\u00fcr MA, Akbal C. OAB-V8 overactive bladder inquiry form validation study (Article in Turkish). \u00dcroloji B\u00fclteni. 2012, 21:113-6.","journal-title":"\u00dcroloji B\u00fclteni"},{"key":"ref13","unstructured":"European Association of Urology. EAU guidelines on urinary incontinence. (2019). Accessed: December 26, 2022: https:\/\/uroweb.org\/education-events\/eau-guidelines-on-urinary-incontinence."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/2042098616659412","article-title":"Mirabegron in overactive bladder patients: efficacy review and update on drug safety","volume":"7","author":"Warren K","year":"2016","unstructured":"Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016, 7:204-16. 10.1177\/2042098616659412","journal-title":"Ther Adv Drug Saf"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple CR","year":"2014","unstructured":"Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014, 33:17-30. 10.1002\/nau.22505","journal-title":"Neurourol Urodyn"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman K","year":"2014","unstructured":"Maman K, Aballea S, Nazir J, et al.. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014, 65:755-65. 10.1016\/j.eururo.2013.11.010","journal-title":"Eur Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar V","year":"2013","unstructured":"Khullar V, Amarenco G, Angulo JC, et al.. Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013, 63:283-95. 10.1016\/j.eururo.2012.10.016","journal-title":"Eur Urol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-013-2042-x","article-title":"A phase II dose-ranging study of mirabegron in patients with overactive bladder","volume":"24","author":"Chapple CR","year":"2013","unstructured":"Chapple CR, Dvorak V, Radziszewski P, et al.. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013, 24:1447-58. 10.1007\/s00192-013-2042-x","journal-title":"Int Urogynecol J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies","volume":"67","author":"Nitti VW","year":"2013","unstructured":"Nitti VW, Khullar V, van Kerrebroeck P, et al.. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013, 67:619-32. 10.1111\/ijcp.12194","journal-title":"Int J Clin Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1149806","article-title":"Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics","volume":"32","author":"Wagg A","year":"2016","unstructured":"Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016, 32:621-38. 10.1185\/03007995.2016.1149806","journal-title":"Curr Med Res Opin"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-017-3377-5","article-title":"A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)","volume":"29","author":"Staskin D","year":"2018","unstructured":"Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Int Urogynecol J. 2018, 29:273-83. 10.1007\/s00192-017-3377-5","journal-title":"Int Urogynecol J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131786-the-efficiency-and-safety-of-mirabegron-monotherapy-for-the-treatment-of-urge-incontinence-in-women-aged-80-years","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:54Z","timestamp":1707508494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131786-the-efficiency-and-safety-of-mirabegron-monotherapy-for-the-treatment-of-urge-incontinence-in-women-aged-80-years"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.33685","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}